JSJuexian Song

Juexian Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juexian Song has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating Traditional Chinese Medicine Syndrome Score with NIHSS for Improved Prognostic Evaluation in Acute Ischemic Stroke

    by Lingqian He, Xinyu Wang, Qiqi Cui, Penglin Xu, Haoran Sun, Ping Liu, Juexian Song

    Aim: To investigate whether the traditional Chinese medicine (TCM) heat syndrome score (HSS), alone or in interaction with the National Institutes of Health Stroke Scale (NIHSS), provides additional prognostic information for 90-day functional outcomes in patients with large-artery atherosclerotic acute ischemic stroke (AIS). Methods: A total of 149 patients with large-artery atherosclerotic AIS admitted to Xuanwu Hospital, Capital Medical University, between December 2017 and December 2023 were retrospectively included. Demographic characteristics, medical history, laboratory parameters, clinical scores, and inflammatory indices, the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI), were collected or calculated. Multivariable logistic regression was used to evaluate factors associated with poor 90-day functional outcome (mRS ≥3). An interaction term (NH), defined as the product of mean-centered NIHSS and HSS, was evaluated in the prognostic model. Firth penalized logistic regression, subgroup and sensitivity analyses, ROC analysis, bootstrap internal validation, and restricted cubic spline analysis were additionally performed. Results: Among 149 patients, 55 (36.9%) had a poor functional outcome at 90 days. HSS alone was not independently associated with poor outcome, whereas lnNLR remained independently associated with outcome after multivariable adjustment. NH was significantly associated with poor functional outcome in the primary model (OR = 1.072, P = 0.005), and the association remained robust in Firth penalized regression and sensitivity analyses. Adding NH to the Base model resulted in a modest numerical increase in discrimination (AUC = 0.795 vs. 0.760), although the difference was not statistically significant by DeLong’s test ( P = 0.098). Exploratory mediation analysis provided no evidence that C-reactive protein (CRP) mediated the association between NH and poor functional outcome. Conclusion: The interaction between NIHSS and HSS was associated with 90-day functional outcome in patients with large-artery atherosclerotic AIS and may provide additional prognostic information beyond conventional clinical factors. However, its incremental predictive value was modest and requires confirmation in larger independent external validation cohorts before clinical implementation.

  • Open Access

    Heat syndrome types prediction of traditional Chinese medicine in acute ischemic stroke through deep learning: a pilot study

    by Xiongwu Yu, Lingqian He, Qi Wang, Zhongyun Zhang, Huaiqiu Zhu, Juexian Song

    Integrating Chinese medicine and biomedicine for treating acute ischemic stroke (AIS) presents a promising strategy. Accurately predicting Traditional Chinese Medicine (TCM) heat syndrome types in AIS patients is crucial for guiding appropriate medication use within this combined treatment strategy. In this study, a clinical cohort including TCM syndromes, laboratory markers, and baseline assessments, were collected from 193 AIS patients. We developed a deep learning method with Convolutional Neural Networks (CNNs) to predict heat syndrome types in AIS patients by integrating TCM pattern characteristics and laboratory indicators. Feature importance was assessed using SHapley Additive exPlanations (SHAP) and permutation importance, and partial dependence plots (PDP) were used to explore the relationships between features and predictions. The model with the comprehensive feature dataset achieved an accuracy of 0.95, F1 score of 0.95, and AUC of 0.91 on the test set, exhibiting better performance overall compared to predictions based solely on TCM pattern characteristics or laboratory indicators. Key factors associated with the heat syndrome types included Tongue Teeth Marks, Stool, Sweat, Tongue Fissures, glycated hemoglobin (HbA1c), triglycerides (TG), fasting blood glucose (FBG) and total cholesterol (CHO). In conclusion, this study confirms the effectiveness of the CNN model in predicting heat syndrome types in AIS patients when incorporating TCM patterns with biochemical laboratory indicators.


  • Open Access

    Association of inflammatory burden index with prognosis as well as stroke-associated pneumonia in non-surgical patients with spontaneous intracerebral hemorrhage

    by Xinyu Wang, Lingqian He, QiQi Cui, Jiapeng Zhao, Juexian Song

    Aim: To assessment the new biomarker, the inflammatory burden index (IBI) and their correlations with clinical outcome as well as stroke-associated pneumonia (SAP) of ICH patients.Methods: Patients diagnosed as spontaneous intracranial hemorrhage (SICH) were retrospectively screened from December 2018 to December 2022. The IBI was formulated as C-reactive protein×neutrophils/lymphocytes. In addition, systemic-inflammatory indices including ratios of neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte (PLR),and patelet-to-neutrophil (PNR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) on admission also were calculated. The primary outcome measure was 90-day functional outcome and the occurrence of SAP, with an mRS 3–6 score representing a unfavorable outcome. We used ROC curves to evaluate the diagnostic value of these differences. Univariate and multivariable analyses was conducted to identify the factors independently associated with 3 months unfavorable functional outcomes and stroke-associated pneumonia.Results: A total of 209 patients were enrolled, of which 144 (68.9%) had unfavorable 90-day functional outcome, and 89 (42.1%) ICH patients developed SAP. Elevated IBI is an independent predictor for both stroke-associated pneumonia (SAP) and unfavorable 3-month outcomes in acute ICH patients, and showed a good predictive ability for SAP (AUC = 0.811, p < 0.001) and poor prognosis at 3 months (AUC = 0.745, p < 0.001).Conclusion: Inflammatory biomarker index (IBI) are predictive of 90-day functional outcome and the SAP occurrence in patients with ICH.


  • Open Access

    Efficacy and Safety of Early Use of Naoxueshu Within 72 hours in the Treatment of Spontaneous Intracerebral Hemorrhage: A Real-World Retrospective Cohort Study

    by Xinyu Wang, Zhiyuan Shang, Jiapeng Zhao, Hongping Hou, Ye Li, Juexian Song

    Background: Naoxueshu Oral Liquid (NXS) is the only traditional Chinese medicine approved for the treatment of spontaneous intracerebral hemorrhage (ICH). While randomized controlled trials have demonstrated its ability to promote hematoma absorption and improve neurological function prognosis, the efficacy and safety of NXS early use (within 72 hours) remain unclear. This study aims to evaluate the efficacy and safety of early NXS administration (within 72 hours) in a real-world setting. Methods: Data were collected from 34 tertiary hospitals in China. Patients were enrolled from March 25, 2019 to December 31, 2023. NXS administration was defined as the exposure. The primary outcome was hematoma volume at 14 days after onset. We employed the 1:1 propensity score matching (PSM) method to deal with confounding factors. Results: A total of 1602 patients were enrolled after PSM, including 872 NXS users (exposed group) and 730 non-NXS users (control group). At baseline, there was no significant difference in hematoma volumes between the two groups (21.46± 19.47 vs 22.01± 14.26mL, P=0.55), the NXS group showed significantly less hematoma volume by day 14 (6.87± 8.62 vs 5.43± 5.35mL, P< 0.001). There was no statistically significant difference in the incidence rate of serious adverse events between the two groups. Subgroup analysis indicated that NXS might have a more pronounced effect on hematoma absorption in supratentorial hemorrhage patients, with earlier administration potentially enhancing efficacy. Conclusion: This retrospective study explored the efficacy and safety of NXS in promoting hematoma absorption within 72 hours in real-world ICH patients, but its effect on short-term neurological improvement remains inconclusive. Further studies with longer follow-up periods and more comprehensive functional assessments are warranted to explore the long-term neurological benefits of NXS in ICH patients.


  • Open Access

    Effectiveness of Compound Dilong Capsules in Patients with Asymptomatic Cerebral Carotid Artery Stenosis: A Retrospective Case-Control Study

    by Xinzuo Qin, Xu Guo, Yijiang Liu, Zijian Wang, Xinyu Wang, Qi Wan, Mingjie Gao, Juexian Song

    Purpose: Asymptomatic cerebral carotid artery stenosis (ACCAS) benefits from secondary prevention via statins and antiplatelets; nonetheless, the impact of medication alone is often limited. Evidence has suggested enhanced therapeutic outcomes when Chinese patent medicine—specifically, compound dilong capsules (CDC)—is integrated with conventional secondary prevention measures. Patients and Methods: We retrospectively analyzed 319 ACCAS patients from January 2018 to December 2022 at Xuanwu Hospital, Capital Medical University. Depending on the clinical outcomes—improvement or stabilization versus progression—patients were classified into effective or ineffective treatment groups. Patient medical records and questionnaire responses were the primary data sources. The study accounted for demographic variables, clinical history, and medication details, with the primary focus on CDC use and its duration. Treatment outcomes were gauged alongside Transcranial color-coded sonography and Carotid Doppler ultrasonography findings. We employed both univariate and multivariate statistical methods to assess the data. Results: CDC administration (aOR=2.51, 95% CI 1.39– 4.54, P=0.002) and extended usage beyond six months (aOR=3.54, 95% CI 1.71– 7.32, P=0.001) demonstrate a statistically significant correlation with treatment efficacy. Gender (aOR=2.54, 95% CI 1.30– 5.00, P=0.007), hypertension management (aOR=0.56, 95% CI 0.33– 0.95, P=0.031), and antiplatelet therapy with aspirin (aOR=9.53, 95% CI 1.15– 78.89, P=0.037) or clopidogrel (aOR=9.97, 95% CI 1.10– 90.12, P=0.041) also influenced the therapeutic outcome significantly. Conclusion: Incorporating CDC as part of a secondary prevention strategy for over six months can beneficially modulate and limit the progression of vascular stenosis in ACCAS. These findings underscore the value of combining traditional Chinese medicine with modern pharmacological interventions in ACCAS management.


  • Open Access

    Ruyi Zhenbao Tablet and Baimai Ointment Therapy in Acute Ischemic Stroke: A Study Protocol for a Multi-Center, Randomized, Double-blinded, and Parallel-Controlled Trial

    by Xinzuo Qin, Liyuan Huang, Haiyue Zhang, Zijian Wang, Xiao Wu, Cuomu Mingji, Qi Wan, Haiqing Song, Juexian Song

    Introduction: Stroke is characterized by high incidence, recurrence rate, and mortality. Patients with acute ischemic stroke (AIS) who are ineligible for acute revascularization therapy require more effective medication treatments. A previous clinical study showed that Ruyi Zhenbao tablets and Baimai ointments might be effective against AIS; however, high-quality clinical evidence supporting their application in AIS is lacking. To explore the efficacy of the two classic Tibetan medicines in the treatment of AIS, a randomized clinical trial will be conducted in patients with AIS who are not eligible for thrombolytic treatment. Methods: A prospective, randomized, multiple-center, double-blinded, placebo-controlled, and parallel-group trial will be conducted. We shall randomize 480 eligible participants to either the intervention or the control group. The distribution ratio of each group will be 1:1:1:1, including 120 patients each in the dual-medication group, the Baimai ointment group, the Ruyi Zhenbao tablet group, and the placebo group. Participants will be treated with medication for 8 weeks, and they will receive three follow-up visits: at 4 weeks (D29), 8 weeks (D56), and 90 days (D90) after commencing treatment. The primary outcome will be D90 change in the simplified Fugl-Meyer score from baseline to posttreatment. The secondary outcomes are as follows: D29 change of simplified Fugl-Meyer score from baseline to posttreatment; proportion of participants whose D29 NIHSS scores decreased by four or more points from baseline D90 proportion of subjects with mRS score of 0–2 (inclusive); D90 proportion of subjects with Barthel index score ≥95; D90 incidence of cardiovascular and cerebrovascular events. Safety endpoint includes mortality within 90 days; proportion of subjects with adverse events/serious adverse events within 90 days. Conclusion: This research protocol lays a solid groundwork for its practical execution. This study is poised to serve as a reference for other Tibetan medicine researchers, contributing to the reduction of stroke-related expenditures globally and, in turn, benefiting a broader population of stroke patients.


  • Open Access

    A literature review on Epimedium, a medicinal plant with promising slow aging properties

    by Wei Zhuang, Nan Sun, Chengjuan Gu, Shimeng Liu, Yujiao Zheng, Han Wang, Xiaolin Tong, Juexian Song


  • Open Access

    Integrated Traditional Chinese Medicine Improves Functional Outcome in Acute Ischemic Stroke: From Clinic to Mechanism Exploration With Gut Microbiota

    by Qian Guo, Can Ni, Linjing Li, Mo Li, Xiaoqing Jiang, Li Gao, Huaiqiu Zhu, Juexian Song

    As a life-threatening disease, stroke is the leading cause of death and also induces adult disability worldwide. To investigate the efficacy of the integrated traditional Chinese medicine (ITCM) on the therapeutic effects of acute ischemic stroke (AIS) patients, we enrolled 26 patients in the ITCM [Tanhuo decoction (THD) + Western medicine (WM)] group and 23 in the WM group. Thirty healthy people were also included in the healthy control (HC) group. ITCM achieved better functional outcomes than WM, including significant reduction of the phlegm-heat syndrome and neurological impairment, and improvement of ability. These facts were observed in different pretreatment gut enterotypes. In this paper, we collected the stool samples of all participants and analyzed the 16S rRNA sequence data of the gut microbiota. We identified two enterotypes (Type-A and Type-B) of the gut microbial community in AIS samples before treatment. Compared to Type-B, Type-A was characterized by a high proportion of Bacteroides, relatively high diversity, and severe functional damage. In the ITCM treatment group, we observed better clinical efficacy and positive alterations in microbial diversity and beneficial bacterial abundance, and the effect of approaching healthy people’s gut microbiota, regardless of gut enterotypes identified in pretreatment. Furthermore, we detected several gut microbiota as potential therapeutic targets of ITCM treatment by analyzing the correlations between bacterial abundance alterations and functional outcomes, where Dorea with the strongest correlation was known to produce anti-inflammatory metabolite and negatively linked to trimethylamine-N-oxide (TMAO), a biomarker of AIS. This study analyzed clinical and gut microbial data and revealed the possibility of a broad application independent of the enterotypes, as well as the therapeutic targets of the ITCM in treating AIS patients with phlegm-heat syndrome.


  • Open Access

    Gut Microbiota‐Related Effects of Tanhuo Decoction in Acute Ischemic Stroke

    by Qian Guo, Xiaoqing Jiang, Can Ni, Linjing Li, Li Chen, Yaqi Wang, Mo Li, Chunhui Wang, Li Gao, Huaiqiu Zhu, et al.

    Acute ischemic stroke (AIS) is a major cause of acquired adult disability and death. Our previous studies proved the efficacy and effectiveness of Tanhuo decoction (THD) on AIS. However, the therapeutic mechanism remains unclear. We recruited 49 AIS patients and 30 healthy people to explore the effects of THD+basic treatment on the poststroke gut microbiota of AIS patients using 16S rRNA sequencing, in which 23 patients received basic treatment (control group) and 26 patients received THD+basic treatment (THD group). By comparing the data before and after treatments, we found the THD group acquired better outcome than the control group on both clinical outcome indices and the characteristics of gut microbiota. In addition to the mediation on short‐chain fatty acid‐ (SCFA‐) producing bacteria in two groups, treatment in the THD group significantly decreased the lipopolysaccharide‐ (LPS‐) producing bacteria to reduce LPS biosynthesis. Besides, the complexity of the cooccurrence of gut microbiota and the competition among LPS‐producing bacteria and opportunistic pathogenetic bacteria were enhanced in the THD group. Treatment in the THD group also exhibited the potential in decreasing genes on the biosynthesis of trimethylamine (TMA), the precursor of Trimethylamine N‐oxide (TMAO), and increasing genes on the degradation of TMA, especially increasing trimethylamine‐corrinoid protein Co‐methyltransferase (mttB) which catabolizes TMA to methane. These results hinted that THD+basic treatment might exert its efficacy by mediating the gut microbiota and microbial metabolites, including LPS and TMAO that aggravate the sterile inflammation and platelet aggregation. Moreover, the well‐fitting regression model results in predicting the clinical outcome with the alteration of gut microbiota proved gut microbiota as a potential indicator of AIS and provided evidence of the communication between the gut and brain of AIS patients.


  • Open Access

    The Relationship of Large‐Artery Atherothrombotic Stroke with Plasma Trimethylamine N‐Oxide Level and Blood Lipid‐Related Indices: A Cross‐Sectional Comparative Study

    by Dongjuan Xu, Wenfeng Zhao, Juexian Song, Lu Yin, Kun Wang, Lianyan Wei, Yunyun Xu, Hongfei Li, Baoquan Min, Ning Tang, et al.

    Objective. The role of trimethylamine N‐oxide (TMAO) in cardiovascular diseases has been highlighted. Nevertheless, the associations of large‐artery atherosclerotic (LAA) stroke with TMAO and blood lipid‐related indices are little investigated. Methods. A cross‐sectional comparative study was performed on 50 patients with LAA stroke and 50 healthy controls. Basic demographic data, common vascular risk factors, and blood lipid‐related indices were collected. Plasma TMAO was detected through liquid chromatography tandem mass spectrometry. Multivariable unconditional logistic regression analyses were run to assess the associations of LAA stroke with plasma TMAO level and blood lipid‐related indices. The area under the curve (AUC) of the receiver operating characteristic (ROC) was computed to assess the diagnostic performance of plasma TMAO level and blood lipid‐related indices for LAA stroke. Results. Compared with healthy controls, the elevated plasma TMAO level (odds ratio [OR], 7.03; 95% confidence interval [CI], 2.86, 17.25; p < 0.01) and Apo‐B (OR, 1.74; 95% CI, 1.06, 2.85; p = 0.03) were observed in LAA stroke patients, while lower Apo‐A1 (OR, 0.56; 95% CI, 0.34, 0.91; p = 0.02), Apo‐A1 to Apo‐B ratio (OR, 0.29; 95% CI, 0.15, 0.56; p < 0.01), and HDL‐C (OR, 0.56; 95% CI, 0.35, 0.91; p = 0.02) were found in LAA stroke patients after adjusted for age and gender. Moreover, plasma TMAO (AUC, 0.89; 95% CI, 0.83, 0.95), Apo‐A1 (AUC, 0.81; 95% CI, 0.72, 0.89), Apo‐B (AUC, 0.81; 95% CI, 0.73, 0.90), Apo‐A1 to Apo‐B ratio (AUC, 0.85; 95% CI, 0.78, 0.93), and HDL‐C (AUC, 0.81; 95% CI, 0.72, 0.89) showed good diagnostic values for LAA stroke in adjusted models. Conclusions. The plasma TMAO level, Apo‐A1, Apo‐B, and HDL‐C are important biomarkers for LAA stroke patients.